First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

BACKGROUND: Previous findings suggested that bevacizumab might be able to improve response rate (RR) in colorectal cancer patients with high lactic dehydrogenase (LDH) basal levels. METHODS: We conducted a phase II trial to prospectively ascertain whether bevacizumab in combination with FOLFIRI coul...

Descripción completa

Detalles Bibliográficos
Autores principales: Giampieri, Riccardo, Puzzoni, Marco, Daniele, Bruno, Ferrari, Daris, Lonardi, Sara, Zaniboni, Alberto, Cavanna, Luigi, Rosati, Gerardo, Pella, Nicoletta, Zampino, Maria Giulia, Sozzi, Pietro, Germano, Domenico, Zagonel, Vittorina, Codecà, Carla, Libertini, Michela, Labianca, Roberto, Cascinu, Stefano, Scartozzi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674092/
https://www.ncbi.nlm.nih.gov/pubmed/28926529
http://dx.doi.org/10.1038/bjc.2017.234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674092/
https://www.ncbi.nlm.nih.gov/pubmed/28926529
http://dx.doi.org/10.1038/bjc.2017.234

Ejemplares similares